CN101981206A - 与癌症干细胞相关的方法和组合物 - Google Patents

与癌症干细胞相关的方法和组合物 Download PDF

Info

Publication number
CN101981206A
CN101981206A CN2009801124738A CN200980112473A CN101981206A CN 101981206 A CN101981206 A CN 101981206A CN 2009801124738 A CN2009801124738 A CN 2009801124738A CN 200980112473 A CN200980112473 A CN 200980112473A CN 101981206 A CN101981206 A CN 101981206A
Authority
CN
China
Prior art keywords
mir
cells
cell
cancer
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801124738A
Other languages
English (en)
Chinese (zh)
Inventor
M·克拉克
Y·西莫诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN101981206A publication Critical patent/CN101981206A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801124738A 2008-02-01 2009-01-30 与癌症干细胞相关的方法和组合物 Pending CN101981206A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2557408P 2008-02-01 2008-02-01
US61/025,574 2008-02-01
PCT/US2009/000593 WO2009097136A1 (en) 2008-02-01 2009-01-30 Methods and compositions relating to carcinoma stem cells

Publications (1)

Publication Number Publication Date
CN101981206A true CN101981206A (zh) 2011-02-23

Family

ID=40913151

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801124738A Pending CN101981206A (zh) 2008-02-01 2009-01-30 与癌症干细胞相关的方法和组合物

Country Status (7)

Country Link
US (1) US20110021607A1 (enExample)
EP (1) EP2247750A4 (enExample)
JP (1) JP2011511634A (enExample)
CN (1) CN101981206A (enExample)
AU (1) AU2009209415A1 (enExample)
CA (1) CA2713469A1 (enExample)
WO (1) WO2009097136A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104415351A (zh) * 2013-09-11 2015-03-18 中国人民解放军第二军医大学东方肝胆外科医院 MicroRNA-429在制备抗肝癌药物中的应用
CN104513852A (zh) * 2014-06-13 2015-04-15 南通大学附属医院 miRNAs在胃癌干细胞中表达谱的分析方法
WO2016177343A1 (zh) * 2015-05-05 2016-11-10 江苏命码生物科技有限公司 一种新的前体miRNA及其在肿瘤治疗中的应用
CN107236749A (zh) * 2017-06-07 2017-10-10 汕头大学医学院附属肿瘤医院 一种光学分子成像报告基因及其用途
CN107858427A (zh) * 2017-10-24 2018-03-30 昆明理工大学 miR‑429在制备乳腺癌诊断和检测试剂盒中的应用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110172293A1 (en) * 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
EP3181705A1 (en) 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
EP2316972A1 (en) * 2009-10-29 2011-05-04 Deutsches Krebsforschungszentrum Circulating miRNAs as non-invasive markers for diagnosis and staging in prostate cancer
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US20120156246A1 (en) * 2010-06-16 2012-06-21 Bamdad Cynthia C Reprogramming cancer cells
EP2638159B1 (en) * 2010-11-11 2019-04-24 University of Miami Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
US8895509B2 (en) 2010-11-23 2014-11-25 Georgia Tech Research Corporation MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells
TW201239097A (en) * 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
CN102168085A (zh) * 2011-01-31 2011-08-31 中山大学肿瘤防治中心 抑制miR-130b基因表达的siRNA和表达载体及其在制备提高肝癌治疗效果的药物中的应用
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
WO2013009705A2 (en) * 2011-07-09 2013-01-17 The Trustees Of Columbia University In The City Of New York Biomarkers, methods, and compositions for inhibiting a multi-cancer mesenchymal transition mechanism
WO2013048345A1 (en) * 2011-09-28 2013-04-04 Agency For Science, Technology And Research Methods and pharmaceutical compositions for treating cancer
US9352039B2 (en) * 2012-02-09 2016-05-31 The Regents Of The University Of Michigan Method of reducing the number of EMT and MET type breast cancer stem cells
WO2013190091A1 (en) * 2012-06-21 2013-12-27 Ruprecht-Karls-Universität Heidelberg CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER
US20150344961A1 (en) * 2012-09-11 2015-12-03 New York University Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
CN103834692B (zh) * 2014-02-27 2016-03-30 南京医科大学 一种用于表达lncRNA的慢病毒载体及其应用
US9631194B2 (en) * 2014-04-04 2017-04-25 Beth Israel Deaconess Medical Center Methods and compositions for use in treatment of FOXP2-related cancers
US10568901B2 (en) 2015-07-15 2020-02-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Micro-RNA for the treatment of malignant solid tumors and metastasis
WO2017207623A1 (en) * 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
US20190242900A1 (en) * 2016-10-10 2019-08-08 Kun-Chih Tsai A novel invadopodia-specific marker of invasive cancer stem cells and the use thereof
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US20220275455A1 (en) * 2019-07-08 2022-09-01 Preferred Networks, Inc. Data processing and classification for determining a likelihood score for breast disease
KR102414106B1 (ko) * 2020-03-12 2022-06-29 (주) 바이오인프라생명과학 유방암 진단용 다중 바이오마커 및 이의 용도
US20230140044A1 (en) * 2020-03-20 2023-05-04 University Of Massachusetts Micrornas for the prevention of clinical venous thromboembolic disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO2008095096A2 (en) * 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer
WO2010056737A2 (en) * 2008-11-11 2010-05-20 Mirna Therapeutics, Inc. Methods and compositions involving mirnas in cancer stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU FENGYAN ET AL.: "Iet-7 regulates self renewal and tumorigenicity of breast cancer cells", 《CELL》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104415351A (zh) * 2013-09-11 2015-03-18 中国人民解放军第二军医大学东方肝胆外科医院 MicroRNA-429在制备抗肝癌药物中的应用
CN104513852A (zh) * 2014-06-13 2015-04-15 南通大学附属医院 miRNAs在胃癌干细胞中表达谱的分析方法
CN104513852B (zh) * 2014-06-13 2016-08-24 南通大学附属医院 miRNAs在胃癌干细胞中表达谱的分析方法
WO2016177343A1 (zh) * 2015-05-05 2016-11-10 江苏命码生物科技有限公司 一种新的前体miRNA及其在肿瘤治疗中的应用
US10533173B2 (en) 2015-05-05 2020-01-14 Jiangsu Micromedmark Biotech Co., Ltd. Precursor miRNA and applications in tumor therapy thereof
CN107236749A (zh) * 2017-06-07 2017-10-10 汕头大学医学院附属肿瘤医院 一种光学分子成像报告基因及其用途
CN107858427A (zh) * 2017-10-24 2018-03-30 昆明理工大学 miR‑429在制备乳腺癌诊断和检测试剂盒中的应用
CN107858427B (zh) * 2017-10-24 2021-03-02 昆明理工大学 miR-429在制备乳腺癌诊断和检测试剂盒中的应用

Also Published As

Publication number Publication date
CA2713469A1 (en) 2009-08-06
EP2247750A4 (en) 2011-10-26
EP2247750A1 (en) 2010-11-10
AU2009209415A1 (en) 2009-08-06
US20110021607A1 (en) 2011-01-27
WO2009097136A1 (en) 2009-08-06
JP2011511634A (ja) 2011-04-14

Similar Documents

Publication Publication Date Title
CN101981206A (zh) 与癌症干细胞相关的方法和组合物
Ge et al. Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis
Zheng et al. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway
Wu et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis
Wang et al. LncRNA HCP5 promotes triple negative breast cancer progression as a ceRNA to regulate BIRC3 by sponging miR‐219a‐5p
Parikh et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition
Celià-Terrassa et al. Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis
Busch et al. The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family
Wang et al. Epidermal growth factor receptor‐regulated miR‐125a‐5p–a metastatic inhibitor of lung cancer
Jones et al. miRNA signatures associate with pathogenesis and progression of osteosarcoma
CN102007223B (zh) 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物
JP5931050B2 (ja) ｍｉＲ−１５５によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法
Zhou et al. MiR-339-5p regulates the growth, colony formation and metastasis of colorectal cancer cells by targeting PRL-1
US9315809B2 (en) Differentially expressed microRNA molecules for the treatment and diagnosis of cancer
Ge et al. Strand-specific in vivo screen of cancer-associated miRNAs unveils a role for miR-21∗ in SCC progression
Chen et al. miR‐490‐5p suppresses tumour growth in renal cell carcinoma through targeting PIK3CA
US20110152357A1 (en) Micro-RNA-Based Compositions and Methods for the Diagnosis, Prognosis and Treatment of Multiple Myeloma
Lulli et al. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal
Liu et al. FUS‐induced circular RNA ZNF609 promotes tumorigenesis and progression via sponging miR‐142‐3p in lung cancer
Zhi et al. Circular RNA profiling identifies circ102049 as a key regulator of colorectal liver metastasis
Grobbelaar et al. The role of MicroRNA in paediatric acute lymphoblastic leukaemia: challenges for diagnosis and therapy
JP5931897B2 (ja) マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
Bharambe et al. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas
Zhang et al. RETRACTED: LncRNA PCAT1 promotes metastasis of endometrial carcinoma through epigenetical downregulation of E-cadherin associated with methyltransferase EZH2
Wang et al. Circular RNA CircPPP1CB suppresses tumorigenesis by interacting with the MiR-1307-3p/SMG1 axis in human bladder cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American California

Applicant after: The Board of Trustees of the Leland Stanford Junior University

Address before: American California

Applicant before: The Board of Trustees of the Leland Stanford Junior Univ.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV. TO: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110223